ICICI Securities Ltd | Retail Equity Research Revenues declined 2.2% YoY to | 6977 crore (I-direct estimate: | 6719 crore) mainly due to 7% YoY decline in the US to | 2370 crore (I-direct estimate: | 2073 crore). The decline in the US was due to high base of gGleevec (oncology) and gBenicar (CVS) EBITDA margins improved 245 bps to 24.1% (I-direct estimates of 20.9%) mainly due to strong gross margins. Gross margins improved 539 bps to 74.6% (I-direct estimates of 68.4%). EBITDA increased...